Thought Leadership
FDA's First Biosimilar Approval Greeted with Optimism; Naming, Pricing Still Issues
March 9, 2015
John Aquino
Bloomberg BNA Life Science’s Law & Industry Report

Axinn Counsel Stacie Ropka was quoted in the Bloomberg BNA Life Science’s Law & Industry Report article, "FDA's First Biosimilar Approval Greeted with Optimism; Naming, Pricing Still Issues."

Click here to access the article.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.